Evaluation reports characteristics of patients initiating subcutaneous efgartigimod for CIDP, indicating important treatment insights.
To evaluate characteristics of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) initiating subcutaneous efgartigimod (SC-EFG).
No takes yet. Share an insight, caveat, or question.
Karkare et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: